Medistim (MEDI) Q3 2025 earnings summary

Executive summary

• Achieved record third quarter with NOK 166.8 million in revenues, up 25.7% year-over-year, and EBIT of NOK 40.6 million, up 27.1%.

• Year-to-date revenues reached NOK 517.5 million, up 25.8%, and EBIT at NOK 153.9 million, up 46.2%.

• Americas and APAC led growth, with Americas up 35.7% and APAC up 194% in Q3; EMEA declined 11.8% in Q3.

• Imaging product sales rose 39.7% in Q3 and 52.4% YTD; cardiac segment up 36.9% in Q3.

• Launched MiraQ INTUI software platform and enhanced sales force training initiatives.

Financial highlights

• Gross margin improved to 81.5% in Q3 (80.3% last year); YTD gross margin at 82.2% (80.5%).

• Profit after tax for Q3 was NOK 34.7 million, up 48% year-over-year; YTD profit after tax reached NOK 121.1 million, up 47%.

• Earnings per share for Q3 NOK 1.90 (NOK 1.28 last year); YTD NOK 6.63 (NOK 4.51 last year).

• Strong cash flow from operations: NOK 69.1 million in Q3, NOK 125.6 million YTD; cash position at NOK 157.7 million.

• Equity ratio at 72.8% by quarter end; no interest-bearing bank debt.

Outlook and guidance

• Americas expected to remain the main growth driver, with strategic investments in sales force and market awareness.

• APAC, especially China and India, seen as medium- to long-term growth engines.

• Focus on expanding in Vascular surgery and converting Flow-only markets to Flow-and-Imaging.

• Entering 2025 with strong momentum, supported by new software launches and product innovation.

• Inventory levels expected to decrease as previously committed orders are fulfilled.